Lambert, Cécile ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Borderie, D.; INSERM UMR 1124, Laboratory of Pharmacology, Toxicology and Cell Signaling, University Paris-Descartes, Paris, France, Department of Automated Biological Diagnostic, Cochin Hospital, APHP, University Paris Descartes, Paris, France
Dubuc, J.-E.; Orthopaedic Department, University Hospital Saint-Luc, Brussels, Belgium
Rannou, F.; INSERM UMR 1124, Laboratory of Pharmacology, Toxicology and Cell Signaling, University Paris-Descartes, Paris, France, Department of Physical Medicine and Rehabilitation, Rheumatology Institute, Cochin Hospital, APHP, University Paris Descartes, Paris, France
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Language :
English
Title :
Type II collagen peptide Coll2-1 is an actor of synovitis
Publication date :
2019
Journal title :
Osteoarthritis and Cartilage
ISSN :
1063-4584
eISSN :
1522-9653
Publisher :
W.B. Saunders Ltd
Volume :
27
Issue :
11
Pages :
1680-1691
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
SPW - Service public de Wallonie Économie, Emploi, Recherche French Society of Rheumatology
Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil. 2015;23(8):1233-1241. doi:10.1016/j.joca.2015.03.036
de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr Cartil. 2012;20(12):1484-1499. doi:10.1016/j.joca.2012.08.027
Liu-Bryan R. Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep. 2013;15(5):323. doi:10.1007/s11926-013-0323-5
Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249-257. doi:10.1016/j.bone.2012.02.012
Nefla M, Holzinger D, Berenbaum F, Jacques C. The danger from within: alarmins in arthritis. Nat Rev Rheumatol. 2016;12(11):669-683. doi:10.1038/nrrheum.2016.162
Gallo J, Raska M, Konttinen YT, Nich C, Goodman SB. Innate immunity sensors participating in pathophysiology of joint diseases: a brief overview. J Long Term Eff Med Implants. 2014. doi:10.1016/j.ygyno.2014.12.035.Pharmacologic
Kandahari AM, Yang X, Dighe AS, Pan D, Cui Q. Recognition of Immune Response for the Early Diagnosis and Treatment of Osteoarthritis. J Immunol Res. 2015;2015:192415. doi:10.1155/2015/192415
Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263-1267. doi:10.1136/ard.2004.025270
Da RR, Qin Y, Baeten D, Zhang Y. B cell clonal expansion and somatic hypermutation of Ig variable heavy chain genes in the synovial membrane of patients with osteoarthritis. J Immunol. 2007;178(1):557-565. http://www.ncbi.nlm.nih.gov/pubmed/17182596.
Wu W, Billinghurst RC, Pidoux I, et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum. 2002;46(8):2087-2094. doi:10.1002/art.10428
Klatt AR, Paul-Klausch B, Klinger G, et al. A critical role for collagen II in cartilage matrix degradation: collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res. 2009;27(1):65-70. doi:10.1002/jor.20716
Ruettger A, Schueler S, Mollenhauer JA, Wiederanders B. Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J Biol Chem. 2008;283(2):1043-1051. doi:10.1074/jbc.M704915200
Fichter M, Korner U, Schomburg J, Jennings L, Cole AA, Mollenhauer J. Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytes. J Orthop Res. 2006;24(1):63-70. doi:10.1002/jor.20001
Tchetina E V, Kobayashi M, Yasuda T, Meijers T, Pidoux I, Poole AR. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biol. 2007;26(4):247-258. doi:10.1016/j.matbio.2007.01.006
Yasuda T. Type II collagen peptide stimulates Akt leading to nuclear factor-kappaB activation: its inhibition by hyaluronan. Biomed Res. 2014;35(3):193-199. http://www.ncbi.nlm.nih.gov/pubmed/24942858.
Schmal H, Bernstein A, Feucht MJ, et al. Prospective Clinical Trial for Septic Arthritis: Cartilage Degradation and Inflammation Are Associated with Upregulation of Cartilage Metabolites. Mediat Inflamm. 2016;2016:5491971. doi:10.1155/2016/5491971
Ritter SY, Collins J, Krastins B, et al. Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis. Arthritis Res Ther. 2014;16(5):456. doi:10.1186/s13075-014-0456-6
Huebner JL, Williams JM, Deberg M, Henrotin Y, Kraus VB. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthr Cartil. 2010;18(3):397-405. doi:10.1016/j.joca.2009.09.011
Deberg M, Labasse A, Christgau S, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2005;13(3):258-265. doi:10.1016/j.joca.2004.12.002
Deberg M, Dubuc JE, Labasse A, et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis. 2008;67(2):168-174. doi:10.1136/ard.2007.073452
Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980;102(2):344-352. http://www.ncbi.nlm.nih.gov/pubmed/6158890. Accessed August 27, 2018.
Hegen M, Keith JC, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1505-1515. doi:10.1136/ard.2007.076430
Williams RO. Collagen-Induced Arthritis as a Model for Rheumatoid Arthritis. In: Tumor Necrosis Factor. Vol 98. New Jersey: Humana Press; 2004:207-216. doi:10.1385/1-59259-771-8:207
RIOJA I, BUSH KA, BUCKTON JB, DICKSON MC, LIFE PF. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol. 2004;137(1):65-73. doi:10.1111/j.1365-2249.2004.02499.x
Joosten LA, Lubberts E, Helsen MM, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1999;1(1):81. doi:10.1186/ar14
Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol. 2007;19(5):444-450. doi:10.1097/BOR.0b013e32829fb3b5
Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther. 2000;6(2):71-79. http://www.ncbi.nlm.nih.gov/pubmed/11108572.
Gomez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G. TLR4 signalling in osteoarthritis–finding targets for candidate DMOADs. Nat Rev Rheumatol. 2015;11(3):159-170. doi:10.1038/nrrheum.2014.209
Goldring MB. Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis. Ther Adv Musculoskelet Dis. 2012;4(4):269-285. doi:10.1177/1759720X12448454
Arii K, Kumon Y, Sugahara K, et al. Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B. Mol Immunol. 2008;45(2):463-469. doi:10.1016/j.molimm.2007.05.020
Pantano C, Reynaert NL, van der Vliet A, Janssen-Heininger YMW. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal. 2006;8(9-10):1791-1806. doi:10.1089/ars.2006.8.1791
Bonizzi G, Piette J, Merville MP, Bours V. Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol. 2000;59(1):7-11. http://www.ncbi.nlm.nih.gov/pubmed/10605929. Accessed October 22, 2018.
Rigoglou S, Papavassiliou AG. The NF-κB signalling pathway in osteoarthritis. Int J Biochem Cell Biol. 2013;45(11):2580-2584. doi:10.1016/J.BIOCEL.2013.08.018
O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13(6):453-460. doi:10.1038/nri3446
Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001;1(4):377-385. http://www.ncbi.nlm.nih.gov/pubmed/15758488.
Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 2010;62(8):2192-2205. doi:10.1002/art.27503